- Home
- CRIS vs ICMB Comparison
CRIS vs ICMB Comparison
Compare CRIS & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRIS | ICMB |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 17.2M |
| IPO Year | 2000 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CRIS | ICMB |
|---|---|---|
| Price | $1.53 | $0.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 262.0K | 28.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 21.74% |
| EPS Growth | ★ 91.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $27.10 | $7.43 |
| Revenue Next Year | $67.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.18 | $0.73 |
| 52 Week High | $6.74 | $3.12 |
Technical Indicators
Market Signals| Indicator | CRIS | ICMB |
|---|---|---|
| Relative Strength Index (RSI) | 28.11 | 51.18 |
| Support Level | $1.54 | $0.86 |
| Resistance Level | $5.55 | $0.89 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | -0.30 | 0.01 |
| Stochastic Oscillator | 0.67 | 78.21 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.